Simply defined, iPledge is a patient safety program for patients on or intending to take isotretinoin and it is designed to prevent harm from coming to unborn children of pregnant women, as well as other potential harmful side effects if not monitored by your provider. In technical terms, it is a REMS (Risk Evaluation and Mitigation Strategy) program implemented through the FDA.
Compounding refers to the process of customizing medications by a professional pharmacist to address the specific needs of an individual patient. This is especially helpful when commercially available medications contain an unwanted inactive ingredient, or are not easy to find, not effective, or not available. It is an encompassing process, allowing pharmacists to alter, combine, or mix various ingredients to create medications not available by manufacturers.